Trulieve Cannabis price target lowered to $37 from $41 at Cantor Fitzgerald

Cantor Fitzgerald analyst Pablo Zuanic lowered the firm’s price target on Trulieve Cannabis to $37 from $41 and keeps an Overweight rating on the shares. Trulieve’s Q4 sales were up only 0.5% sequentially, as price-mix was more of a headwind than anticipated, the analyst tells investors in a research note. The firm believes Trulieve is well-placed to benefit from M&A opportunities in the year ahead, and this, combined with ongoing good progress on putting recreational legalization in the Florida November 2024 ballot, bode well for the stock.